India’s 30% cancer-drug margin cap brings relief for patients but risks slowing new treatments

Hospitals broadly welcome the prospect of cheaper oncology medicines, but HCG warns that tighter margins could deter manufacturers from bringing patented and newer treatments to India. The Indian government’s move to cap trade margins at 30% on non-scheduled anti-cancer drugs…













